Trospium chloride
Cobenfy, Trospium (trospium chloride) is a small molecule pharmaceutical. Trospium chloride was first approved as Sanctura on 2004-05-28. It is used to treat overactive urinary bladder and urge urinary incontinence in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| urogenital diseases | D000091642 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cobenfy | New Drug Application | 2024-09-30 |
| trospium chloride | ANDA | 2024-10-30 |
| trospium chloride er | ANDA | 2023-01-31 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
40 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | 3 | — | 1 | 7 | 6 | 17 |
| Urinary incontinence | D014549 | HP_0000020 | R32 | 2 | — | 1 | 4 | — | 7 |
| Enuresis | D004775 | — | R32 | 2 | — | 1 | 3 | — | 6 |
| Urge urinary incontinence | D053202 | EFO_0006865 | N39.41 | — | — | 1 | 1 | — | 2 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | 1 | — | — | 1 | — | 2 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | 1 | — | 2 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | 1 | — | 1 |
| Cognition | D003071 | EFO_0003925 | — | — | — | — | 1 | — | 1 |
| Mental competency | D016743 | — | — | — | — | — | 1 | — | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | 1 | 8 | — | — | 10 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | — | 3 | — | — | 3 |
| Psychotic disorders | D011618 | — | F20.81 | — | — | 3 | — | — | 3 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | — | — | 3 | — | — | 3 |
| Interstitial cystitis | D018856 | EFO_1000869 | N30.1 | — | — | 1 | — | — | 1 |
| Pelvic pain | D017699 | — | — | — | — | 1 | — | — | 1 |
| Cystitis | D003556 | EFO_1000025 | N30 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | 2 | — | — | — | 2 |
| Lung diseases | D008171 | HP_0002088 | J98.4 | 1 | 2 | — | — | — | 2 |
| Obstructive lung diseases | D008173 | HP_0006536 | — | 1 | 2 | — | — | — | 2 |
| Respiratory aspiration | D053120 | EFO_1001839 | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Drug interactions | D004347 | — | — | 1 | — | — | — | — | 1 |
| Accidental injuries | D000081084 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urologic diseases | D014570 | — | N39.9 | — | — | — | — | 1 | 1 |
| Urinary bladder diseases | D001745 | — | N32.9 | — | — | — | — | 1 | 1 |
| Ureterolithiasis | D053039 | EFO_1001228 | N20.1 | — | — | — | — | 1 | 1 |
| Ureteral obstruction | D014517 | HP_0006000 | — | — | — | — | — | 1 | 1 |
| Deprescriptions | D000069340 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Trospium chloride |
| INN | trospium chloride |
| Description | Trospium chloride is a muscarinic antagonist used to treat overactive bladder. It has side effects typical of this class of drugs, namely dry mouth, stomach upset, and constipation; these side effects cause problems with people taking their medicine as directed. However it doesn't cause central nervous system side effects like some other muscarinic antagonists. It is in pregnancy category C and is excreted in breast milk.
|
| Classification | Small molecule |
| Drug class | quaternary ammonium derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]21CCCC1)C(O)(c1ccccc1)c1ccccc1.[Cl-] |
Identifiers
| PDB | — |
| CAS-ID | 10405-02-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3084748 |
| ChEBI ID | — |
| PubChem CID | 107979 |
| DrugBank | DBSALT000883 |
| UNII ID | 1E6682427E (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 933 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,600 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use